alea-institute/kl3m-data-sample-004-shuffled huggingface dataset:
<TABLE> <S> <C>

<ARTICLE> 5
<LEGEND>
THIS SCHEDULE CONTAINS SUMMARY FINANCIAL INFORMATION EXTRACTED FROM TEEKAY
SHIPPING CORPORATION AND SUBSIDIARIES CONSOLIDATED FINANCIAL STATEMETNS AND IS
QUALIFIED IN ITS ENTIRETY BY REFERENCE TO SUCH FINANCIAL STATEMENTS.
</LEGEND>
<MULTIPLIER> 1,000
       
<S>                             <C>
<PERIOD-TYPE>                   12-MOS
<FISCAL-YEAR-END>                          MAR-31-1998
<PERIOD-START>                             APR-01-1997
<PERIOD-END>                               MAR-31-1998
<CASH>                                          87,953
<SECURITIES>                                    13,448
<RECEIVABLES>                                   24,327
<ALLOWANCES>                                         0
<INVENTORY>                                          0
<CURRENT-ASSETS>                               139,514
<PP&E>                                       1,798,662
<DEPRECIATION>                                 500,779
<TOTAL-ASSETS>                               1,460,183
<CURRENT-LIABILITIES>                           98,291
<BONDS>                                        672,437
<PREFERRED-MANDATORY>                                0
<PREFERRED>                                          0
<COMMON>                                       261,353
<OTHER-SE>                                     428,102
<TOTAL-LIABILITY-AND-EQUITY>                 1,460,183
<SALES>                                              0
<TOTAL-REVENUES>                               406,036
<CGS>                                                0
<TOTAL-COSTS>                                  100,776
<OTHER-EXPENSES>                               197,620
<LOSS-PROVISION>                                     0
<INTEREST-EXPENSE>                              56,269
<INCOME-PRETAX>                                 70,504
<INCOME-TAX>                                         0
<INCOME-CONTINUING>                             70,504
<DISCONTINUED>                                       0
<EXTRAORDINARY>                                      0
<CHANGES>                                            0
<NET-INCOME>                                    70,504
<EPS-PRIMARY>                                     2.46
<EPS-DILUTED>                                     2.44
        

</TABLE>
This disposition is not appropriate for publication and is not precedent *

except as provided by 9th Cir. R. 36-3.

The panel unanimously concludes this case is suitable for decision **

without oral argument. See Fed. R. App. P. 34(a)(2).

NOT FOR PUBLICATION

UNITED STATES COURT OF APPEALS

 FOR THE NINTH CIRCUIT

UNITED STATES OF AMERICA,

 Plaintiff - Appellee,

 v.

SANTIAGO YANEZ-MARTINEZ,

 Defendant - Appellant.

No. 09-10497

No. 09-10498

D.C. No. 4:09-cr-50058-JMR

D.C. No. 4:09-cr-00400-JMR

MEMORANDUM*

Appeal from the United States District Court

for the District of Arizona

John M. Roll, Chief Judge, Presiding

Submitted December 19, 2011** 

Before: GOODWIN, WALLACE, and McKEOWN, Circuit Judges.

In these consolidated appeals, Santiago Yanez-Martinez appeals from his

guilty-plea conviction and 51-month sentence for reentry after deportation, in

violation of 8 U.S.C. § 1326, and from the revocation of his supervised release and

the 9-month sentence imposed upon revocation. Pursuant to Anders v. California,

FILED

DEC 23 2011

MOLLY C. DWYER, CLERK

U.S. COURT OF APPEALS
2 09-10497

386 U.S. 738 (1967), Yanez-Martinez’s counsel has filed a brief stating there are

no grounds for relief, along with a motion to withdraw as counsel of record. We

have provided the appellant with the opportunity to file a pro se supplemental

brief. No pro se supplemental brief or answering brief has been filed.

With respect to both cases, we dismiss the appeals in light of the valid

appeal waivers. See United States v. Nguyen, 235 F.3d 1179, 1182 (9th Cir. 2000). 

Counsel’s motion to withdraw is GRANTED, and the appeals are

DISMISSED.
§ 357.152 Package inserts for anthelmintic drug products. The labeling of the product contains a consumer package insert which includes the following information: ( a ) A discussion of the symptoms suggestive of pinworm infestation, including a statement that pinworms must be visually identified before taking this medication.
( b ) A detailed description of how to find and identify the pinworm.
( c ) A commentary on the life cycle of the pinworm.
( d ) A commentary on the ways in which pinworms may be spread from person to person and hygienic procedures to follow to avoid such spreading.
( e ) The appropriate labeling information contained in § 357.150
(Collection of information requirement approved by the Office of Management and Budget under control number 0910-0232) [51 FR 27759, Aug. 1, 1986, as amended at 52 FR 2515, Jan. 23, 1987]
Williams, Renee (OST) "jV^CJC^ b6T-0-Sf>/<^^>vy7^ 

Subject: FW: Access Limitations to Chisana ' . :i ;^-.;l 

Original Message 

From: Morris , Ally n D [mailto:Allyn.D.Morris@boeing.com] 

Sent: Tuesday, Apri l 06, 2010 11:26 AM 

To: Little , Cynthia M (DOT) 

Subject: Access Limitations t o Chisana 

Cindie, 

Please maintain Chisana, Docket 98-4574, as one of the essential air service locations. As a 

land owner at Chisana, I have relied on 40-Mile Air to get either people and/or supplies in 

and out of Chisana, including mail services and unexpected medical related issues. Chisana 

doesn't have road access and is over 80 miles from Tok, the closest airport with air service. 

Thank you, 

Allyn Morris 

(425) 299-0622
IN THE SUPREME COURT OF PENNSYLVANIA

EASTERN DISTRICT

COMMONWEALTH OF PENNSYLVANIA,

Respondent

v.

DANTAE JACQUES,

Petitioner

:

:

:

:

:

:

:

:

:

:

:

No. 581 EAL 2019

Petition for Allowance of Appeal 

from the Order of the Superior Court

ORDER

PER CURIAM

AND NOW, this 14th day of April, 2020, the Petition for Allowance of Appeal is 

DENIED.
§ 520.443 Chlortetracycline tablets and boluses. ( a ) *Specifications.* Each tablet contains 25 milligrams (mg) chlortetracycline hydrochloride; each bolus contains 250 or 500 mg chlortetracycline hydrochloride.
( b ) *Sponsors.* See sponsors in § 510.600(c) of this chapter for use as in paragraph (d) of this section. ( 1 ) No. 069043 for use of a 250-mg bolus as in paragraph (d)(1) of this section.
( 2 ) No. 016592 for use of a 25-mg tablet as in paragraph (d)(2) of this section.
( 3 ) No. 016592 for use of a 500-mg bolus as in paragraph (d)(3) of this section.
( c ) *Related tolerances.* See § 556.150 of this chapter.
( d ) *Conditions of use in calves* — ( 1 ) *Amount.* One 250 milligram bolus per 50 pounds of body weight twice a day for 3 to 5 days. ( i ) *Indications for use.* Treatment of bacterial enteritis (scours) caused by *Escherichia coli* and bacterial pneumonia associated with *Pasteurella* spp., *Klesbsiella* spp., and *Haemophilus* spp.
( ii ) *Limitations.* Administer bolus directly by mouth or crush and dissolve in milk or water for drenching or bucket feeding. Do not use for more than 5 days. Do not administer within 24 hours of slaughter. Federal law restricts this drug to use by or on the order of a licensed veterinarian.
( 2 ) *Amount.* One 25 milligram tablet for each 5 pounds of body weight every 12 hours daily for 3 to 5 days. ( i ) *Indications for use.* Control and treatment of bacterial enteritis (scours) caused by *E. coli* and *Salmonella* spp. And bacterial pneumonia associated with *Pasteurella* spp., *Haemophilus* spp., and *Klebsiella* spp., susceptible to chlortetracycline.
( ii ) *Limitations.* Administer tablet directly by mouth or crush and dissolve in water for drenching; if no improvement is noted after 3 days of treatment, consult a veterinarian; do not use for more than 5 days; when feeding milk or milk replacer, administration 1 hour before or 2 hours after feeding; do not administer within 24 hours of slaughter. Federal law restricts this drug to use by or on the order of a licensed veterinarian.
( 3 ) *Amount.* One 500 milligram bolus per 100 pounds of body weight twice a day for 3 to 5 days. ( i ) *Indications for use.* Treatment of bacterial enteritis (scours) caused by *E. coli* and *Salmonella* spp., and bacterial pneumonia associated with *Pasteurella* spp., *Haemophilus* spp., and *Klebsiella* spp., susceptible to chlortetracycline.
( ii ) *Limitations.* Do not use for more than 5 days. Do not administer within 24 hours of slaughter. Federal law restricts this drug to use by or on the order of a licensed veterinarian.
[57 FR 37325, Aug. 18, 1992, as amended at 67 FR 78355, Dec. 24, 2002. Redesignated and amended at 76 FR 49649, Aug. 11, 2011; 78 FR 21059, Apr. 9, 2013; 81 FR 17607, Mar. 30, 2016; 88 FR 16547, Mar. 20, 2023; 88 FR 27698, May 3, 2023; 88 FR 55563, Aug. 16, 2023]
§ 522.1862 Pralidoxime powder for injection. ( a ) *Specifications.* Each vial contains 1 gram (g) of pralidoxime chloride powder for mixing with 20 cubic centimeters of sterile water for injection. Each milliliter of constituted solution contains 50 milligrams (mg) pralidoxime chloride.
( b ) *Sponsor.* See No. 054771 in § 510.600(c) of this chapter.
( c ) *Conditions of use* — ( 1 ) *Amount.* Administer as soon as possible after exposure to the poison. Before administration of the sterile pralidoxime chloride, atropine is administered intravenously at a dosage rate of 0.05 mg per pound of body weight, followed by administration of an additional 0.15 mg of atropine per pound of body weight administered intramuscularly. Then the appropriate dosage of sterile pralidoxime chloride is administered slowly intravenously. The dosage rate for sterile pralidoxime chloride when administered to horses is 2 g per horse. When administered to dogs and cats, it is 25 mg per pound of body weight. For small dogs and cats, sterile pralidoxime chloride may be administered either intraperitoneally or intramuscularly. A mild degree of atropinization should be maintained for at least 48 hours. Following severe poisoning, a second dose of sterile pralidoxime chloride may be given after 1 hour if muscle weakness has not been relieved.
( 2 ) *Indications for use.* It is used in horses, dogs, and cats as an antidote in the treatment of poisoning due to those pesticides and chemicals of the organophosphate class which have anticholinesterase activity in horses, dogs, and cats.
( 3 ) *Limitations.* Federal law restricts this drug to use by or on the order of a licensed veterinarian.
[79 FR 16193, Mar. 25, 2014]
#### § 26.19 Information relating to quality aspects.

The authorities will establish an appropriate means of exchanging information on any confirmed problem reports, corrective actions, recalls, rejected import consignments, and other regulatory and enforcement problems for products subject to this subpart.
<PAGE>   1
[LOGO]                                  [LOGO]

                      SECURITIES & EXCHANGE ACT 1934 REGISTRATION NUMBER 0-22617
                                                                       TSE : MMM

FOR IMMEDIATE RELEASE: MARCH 22, 1999                               NEWS RELEASE


       FURTHER ENCOURAGING RESULTS FROM THE WHITE SILVER MOUNTAIN PROJECT


VANCOUVER, BRITISH COLUMBIA - Minco Mining & Metals Corporation and Teck
Corporation are very pleased to report further encouraging assay results from
diamond drill hole XT6-05 on the White Silver Mountain Project. The assay
results from this hole are as follows:


<TABLE>
<CAPTION>
    Hole         From         To       Interval       Cu          Pb          Zn          Au          Ag
                 (m)         (m)         (m)         (%)         (%)         (%)        (g/t)       (g/t)
<S>            <C>         <C>          <C>         <C>         <C>         <C>         <C>        <C>  
XT6-05          411.8       441.7        29.9        1.29        3.94        7.65        1.62       78.74
Including
                411.8       416.7        4.9         2.77       15.52       25.19        2.74      206.73
                422.4       426.9        4.5         3.22        4.74       10.14        2.92       161.6
                435.1       441.7        6.6         1.05        2.54        7.73        2.87       73.18
</TABLE>


This hole is located on the 9800 section, 100m east of the 9700 section on which
previously released diamond holes XT6-03 and 13-B2 are located (please see the
longitudinal section attached to the news release of February 25, 1999).
Drilling on the property has been temporarily suspended awaiting the arrival of
additional equipment, which is required for greater drilling depth. Drilling
will resume in late April once the equipment arrives on the property.

The following assay results were released previously and are included here with
downhole depth. These holes were completed as part of the Phase I drilling
program currently underway.


<TABLE>
<CAPTION>
    Hole         From         To       Interval       Cu          Pb          Zn          Au          Ag
                 (m)         (m)         (m)         (%)         (%)         (%)        (g/t)       (g/t)
<S>             <C>         <C>          <C>         <C>        <C>         <C>          <C>        <C>   
XT6-01          271.45      272.80       1.35        2.02       15.93       29.78        6.00       390.94
XT6-02          319.45      321.60       2.15        0.54        4.63        6.53        1.63       141.42
XT6-03          349.90      360.00       10.1        1.53        9.32       16.34        3.30       222.60
</TABLE>


                                     - 30 -

For further information please contact Dr. Ken Z. Cai of Minco at 1-888-288-8288
          or (604)688-8002 or Mr. Fred Daley of Teck at (604)687-1117

 The Toronto Stock Exchange has not reviewed and does not accept responsibility
                     for the accuracy of this news release
**Exhibit32.2**

 

**CERTIFICATIONPURSUANT TO18 U.S.C. SECTION 1350,AS ADOPTED PURSUANT TOSECTION 906 OF THE SARBANES-OXLEY ACT OF 2002**

 

The undersigned officer of Altris Software, Inc. (the “Company”) herebycertifies to his knowledge that the Company’s quarterly report on Form 10-Q forthe period ended December 31, 2003 (the “Report”), as filed with theSecurities and Exchange Commission on the date hereof, fully complies with therequirements of Section 13(a) or 15(d), as applicable, of the SecuritiesExchange Act of 1934, as amended, and that the information contained in theReport fairly presents, in all material respects, the financial condition andresults of operations of the Company.  This certification is providedsolely pursuant to 18 U.S.C. Section 1350, as adopted pursuant toSection 906 of the Sarbanes-Oxley Act of 2002, and shall not be deemed tobe a part of the Report or “filed” for any purpose whatsoever.

 
| Dated:  February 13, 2004 |
|-------------------------------------|
|                                |
| /s/ John Low                        |   |
|                                |
| John Low                            |
| Chief Financial Officer             |

 

 

A signed original of this written statement required bySection 906 has been provided to Altris Software, Inc. and will beretained by Altris Software, Inc. and furnished to the Securities and ExchangeCommission or its staff upon request.

 

----
§ 520.903c Febantel and praziquantel paste. ( a ) *Specifications.* Each gram of paste contains 34 milligrams of febantel and 3.4 milligrams of praziquantel.
( b ) *Sponsor.* See No. 058198 in § 510.600(c) of this chapter.
( c ) *Conditions of use* — ( 1 ) *Amount* — ( i ) Dogs and cats (over 6 months of age): 10 milligrams of febantel and 1 milligram of praziquantel per kilogram of body weight (1 gram of paste per 7.5 pounds body weight) administered by mouth or in the food once daily for 3 days.
( ii ) Puppies and kittens (less than 6 months of age): 15 milligrams of febantel and 1.5 milligrams of praziquantel per kilogram of body weight (1 gram of paste per 5 pounds body weight) administered by mouth on a full stomach once daily for 3 days.
( 2 ) *Indications for use.* ( i ) Dogs and puppies: For removal of hookworms (*Ancylostoma caninum* and *Uncinaria stenocephala*), whipworms (*Trichuris vulpis*), ascarids (*Toxocara canis* and *Toxascaris leonina*), and tapeworms (*Dipylidium caninum* and *Taenia pisiformis*).
( ii ) Cats and kittens: For removal of hookworms (*Ancylostoma tubaeforme*), ascarids (*Toxocara cati*) and tapeworms (*Dipylidium caninum* and *Taenia taeniaeformis*).
( 3 ) *Limitations.* Federal law restricts this drug to use by or on the order of a licensed veterinarian.
[50 FR 19167, May 7, 1985, as amended at 53 FR 48533, Dec. 1, 1988; 56 FR 50813, Oct. 9, 1991; 79 FR 28821, May 20, 2014. Redesignated at 85 FR 18119, Apr. 1, 2020; 86 FR 14818, Mar. 19, 2021]
**MPD** IN THE SUPREME COURT OF THE STATE OF MONTANA No. DA 18 - 0393 STATE OF MONTANA,

Plaintiff and Appellee, v. QUINTON RAND SEDERDAHL ,

Defendant and Appellant.

**ORDER** Upon consideration of Appellee’s motion for a 30 - day extension of time, and good cause appearing therefor, IT IS HEREBY ORDERED Appellee is gran ted an extension of time to and including Octo ber 21 , 2020 , within which to prepare, serve, and file its response brief.

Electronically signed by: Mike McGrath Chief Justice, Montana Supreme Court

September 11 2020

09/11/2020

Case Number: DA 18-0393
**Exhibit 31.1**

 

CERTIFICATIONS

 

I, Carl Mostert, certify that:

 

1. I have reviewed thisquarterly report on Form 10-Q of Spescom Software Inc.;

 

2. Based on my knowledge, thisquarterly report does not contain any untrue statement of a material fact oromit to state a material fact necessary to make the statements made, in lightof the circumstances under which such statements were made, not misleading withrespect to the period covered by this quarterly report;

 

3. Based on my knowledge, thefinancial statements, and other financial information included in thisquarterly report, fairly present in all material respects the financialcondition, results of operations and cash flows of the registrant as of, andfor, the periods presented in this quarterly report;

 

4. The registrant’s othercertifying officer and I are responsible for establishing and maintainingdisclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e)and 15d-15(e)) for the registrant and we have:

 

a) designed such disclosurecontrols and procedures, or caused such disclosure controls and procedures tobe designed under our supervision, to ensure that material information relatingto the registrant, including its consolidated subsidiaries, is made known to usby others within those entities, particularly during the period in which thisquarterly report is being prepared;

 

b) evaluated the effectivenessof the registrant’s disclosure controls and procedures and presented in thisquarterly report our conclusions about the effectiveness of the disclosurecontrols and procedures, as of the end of the period covered by this reportbased on such evaluation; and

 

c) disclosed in this report anychange in the registrant’s internal control over financial reporting thatoccurred during the registrant’s most recent fiscal quarter that has materiallyaffected, or is reasonably likely to materially affect, the registrant’sinternal control over financial reporting; and

 

5. The registrant’s othercertifying officers and I have disclosed, based on our most recent evaluationof internal control over financial reporting, to the registrant’s auditors andthe audit committee of registrant’s board of directors (or persons performingthe equivalent functions):

 

a) all significant deficienciesand material weaknesses in the design or operation of internal control overfinancial reporting which are reasonably likely to adversely affect theregistrant’s ability to record, process, summarize and report financialinformation; and

 

b) any fraud, whether or notmaterial, that involves management or other employees who have a significantrole in the registrant’s internal control over financial reporting.

 

 
| Dated:   August 12, 2004 |
|-------------------------------|
|                          |
| /s/ Carl  Mostert             |   |
| Carl Mostert                  |
| Chief  Executive Officer      |

 

----
```

[Congressional Bills 109th Congress]
[From the U.S. Government Publishing Office]
[H. Res. 842 Engrossed in House (EH)]

H. Res. 842

                 In the House of Representatives, U.S.,

                                                          June 7, 2006.
    Resolved, That upon the adoption of this resolution it shall be in order 
without intervention of any point of order to consider in the House the bill 
(H.R. 5254) to set schedules for the consideration of permits for refineries. 
The bill shall be considered as read. The previous question shall be considered 
as ordered on the bill to final passage without intervening motion except: (1) 
one hour of debate equally divided and controlled by the chairman and ranking 
minority member of the Committee on Energy and Commerce; and (2) one motion to 
recommit.

            Attest:

                                                                 Clerk.
```
§ 507.200 Records subject to the requirements of this subpart. ( a ) Except as provided by paragraphs (d) and (e) of this section, all records required by this part are subject to all requirements of this subpart.
( b ) Records obtained by FDA in accordance with this part are subject to the disclosure requirements under part 20 of this chapter.
( c ) All records required by this part must be made promptly available to a duly authorized representative of the Secretary of Health and Human Services for official review and copying upon oral or written request.
( d ) The requirements of § 507.206 apply only to the written food safety plan.
( e ) The requirements of § 507.202(a)(2), (4), and (5) and (b) do not apply to the records required by § 507.7.
Editorial Note on Part 316
Editorial Note: Nomenclature changes to part 316 appear at 69 FR 13717, Mar. 24, 2004.

§ 316.24 Deficiency letters and granting orphan-drug designation. ( a ) FDA will send a deficiency letter to the sponsor if the request for orphan-drug designation lacks information required under §§ 316.20 and 316.21, or contains inaccurate or incomplete information. FDA may consider a designation request voluntarily withdrawn if the sponsor fails to respond to the deficiency letter within 1 year of issuance of the deficiency letter, unless within that same timeframe the sponsor requests in writing an extension of time to respond. This request must include the reason(s) for the requested extension and the length of time of the requested extension. FDA will grant all reasonable requests for an extension. In the event FDA denies a request for an extension of time, FDA may consider the designation request voluntarily withdrawn. In the event FDA considers a designation request voluntarily withdrawn, FDA will so notify the sponsor in writing.
( b ) FDA will grant the request for orphan-drug designation if none of the reasons described in § 316.25 for requiring or permitting refusal to grant such a request applies.
( c ) When a request for orphan-drug designation is granted, FDA will notify the sponsor in writing and will publicize the orphan-drug designation in accordance with § 316.28.
( d ) A sponsor may voluntarily withdraw an orphan-drug designation request or an orphan-drug designation at any time after the request is submitted or granted, respectively, by submitting a written request for withdrawal to FDA. FDA will acknowledge such withdrawal in a letter to the sponsor. Any benefits attendant to designation (such as orphan-exclusive approval) will cease once designation is voluntarily withdrawn, from the date of FDA's acknowledgement letter. If a sponsor voluntarily withdraws designation, FDA will publicize such withdrawal in accordance with § 316.28.
[57 FR 62085, Dec. 29, 1992, as amended at 78 FR 35133, June 12, 2013]